Newron Pharmaceuticals SpA Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/3/2026)
| Balance Sheet | Total Assets | 40,023,710.00 | ROE | -27.80 % |
| Balance Sheet | Total Equity | -11,126,300.00 | ROA | -33.29 % |
| Cashflow | Capital Expenditures | -47,302.00 | P/FCF | 4.89 |
| Cashflow | Free Cash Flow | 32,513,020.00 | – | – |
| Cashflow | Operating Cash Flow | 32,560,322.00 | P/CF | 4.88 |
| Income | Earnings per Share (diluted) | -0.62 | Div. Yield | – |
| Income | Net Income | -13,239,000.00 | P/E | -12.84 |
| Income | Shares Outstanding | 19,963,000.00 | P/B | -14.28 |
| Income | Total Revenue | 19,126,000.00 | P/S | 8.31 |
Ratios calculated on: 10/14/2026
Company Description
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.newron.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more